Clinical Trial Update: A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 pilot trial evaluating recombinant human relaxin in patients with compensated congestive heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Recombinant Human Relaxin (rhRlx) (Relaxin)

Snippet

Sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies | Conditions: Heart Failure, Congestive | Phase 2 | Status: COMPLETED